INTRODUCTION
============

First-generation CARs were comprised of a single intracellular signaling domain derived from ITAM-bearing signaling domain of CD3ζ. Because costimulatory signals such as CD28, 4-1BB, or CD278 were not provided in first-generation CAR-T cells, the clinical responses to tumors were largely insufficient ([@b21-molce-41-8-717]; [@b29-molce-41-8-717]). To enhance the limited anti-tumor efficacy of first-generation CARs, one or two additional costimulatory domains were incorporated into the CD3ζ-based cytoplasmic domain, which resulted in second or third generation CARs. This modification led to a drastic increase in CAR-T cell effector function, persistence, and survival ([@b24-molce-41-8-717]; [@b43-molce-41-8-717]).

Second-generation CAR-T cells have dramatically improved cancer immunotherapy for multiple blood cancers. The initial success of CAR-T cell therapy was driven mainly by CD19 CAR-T cells, especially in B-cell non-Hodgkin lymphoma (B-NHL), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL) ([@b30-molce-41-8-717]). Both CD28 and 4-1BB CD19 CAR constructs have consistently led to high anti-tumor responses in the clinic, achieving a 70--94% complete response rate (CR) in B-ALL, 40--75% in CLL, and 57--68% in B-NHL, culminating in the recent approval of two CD19 CAR-T cell products by the U.S. FDA.

Despite this significant progress in CD19 CAR-T cell therapies, there are still overarching unmet medical needs in the CAR-T cell therapy field. First, the complex process of autologous CAR-T cell production hinders controllable manufacturing and on-time treatment for patients. Second, CAR-T cells can exhibit fratricide, which narrows options for target antigen choice and restricts the development of CAR-T regimens for diverse cancer types. Lastly, T-cell exhaustion and the immunosuppressive tumor microenvironment (TME) jeopardize CAR-T cell efficacy for various solid tumors. These challenges pose significant barriers, both to the commercialization of current CD19 CAR-T therapies and to extensions of the therapy beyond CD19 CAR-T cells.

Gene editing technologies have emerged as promising engineering tools to resolve the limitations mentioned above. The early gene editing technologies, Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs), are chimeric nucleases composed of a unique DNA-binding domain followed by the FokI DNA-cutting nuclease domain. Whereas ZFNs use multiple zinc fingers, each of which contacts 3--4bp of DNA, as their DNA binding domain, TALENs deploy 1bp-recognizing TAL domains as DNA-binding modules ([@b7-molce-41-8-717]). Distinct from these early gene-editing technologies, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) is a two-component system, composed of a guideRNA and the Cas9 protein. The guideRNA mediates base pairing to complementary target DNA, and Cas9 binds with the guideRNA to induce a double strand break in the target DNA region. Because the CRISPR/Cas9 DNA binding site can be designed to target any sequence of interest by simply altering the guid-eRNA without the need for complex protein engineering, the CRISPR system is highly versatile and is emerging as an efficient alternative to conventional programmable nucleases ([@b41-molce-41-8-717]); as such, it is already being tested in CAR-T cell clinical trials ([Table 1](#t1-molce-41-8-717){ref-type="table"}). Here, we summarize the recent use of gene-editing technologies to resolve problems associated with CAR-T cell therapy and discuss the potential safety issues and limitations of gene-edited CAR-T cells.

UNMET MEDICAL NEEDS AND GENE-EDITING STRATEGIES
===============================================

Development of off-the-shelf CAR-T cells
----------------------------------------

There are several barriers to expanding the accessibility of current autologous CAR-T cell therapies. First, quality control for CAR-T cell production is very challenging. The considerable variability of each patient's starting materials significantly impacts both the feasibility of manufacturing and the therapeutic potential of the product ([@b46-molce-41-8-717]). Also, because current autologous CAR-T cell therapy requires multi-site manufacturing, highly consolidated sample collection, CAR-T cell manufacturing, and treatment are crucial to ensure critical quality attributes ([@b19-molce-41-8-717]). Second, the use of CAR-T cell therapy is largely limited by its high price. CD19 CAR-T cell therapy costs \$350,000--\$500,000, not including health care utilization costs and potential mark-ups. The high price is mainly a result of the laborious processes and expenses required for individualized CAR-T production. Lastly, patients with aggressive disease progression may be unable to withstand the delay required for the complicated manufacturing of an autologous CAR-T regimen.

Development of allogeneic CAR-T cell therapy would simplify and resolve some of the challenges associated with the current autologous CAR-T cell therapy manufacturing process. However, the mismatch between major and/or minor histocompatibility antigens from the host and the donor can elicit significant immunological side effects. Therefore, to develop safe and potent allogeneic CAR-T cell therapy, immunological interactions between the host and the donor must be suppressed.

First, graft versus host diseases (GvHD) must be prevented, because GvHD observed in allogeneic hematopoietic cell transplantation induces a significant level of fatal responses in clinical studies ([@b8-molce-41-8-717]; [@b34-molce-41-8-717]). Because T-cell alloreactivity is dependent on the interaction of T-cell receptors (TCRs) with alloantigens presented by human leukocyte antigens (HLAs) ([@b1-molce-41-8-717]), TCR-depleted T-cells do not cause GvH responses when infused into HLA-unmatched patients. Among the components of the TCR complex that may be targeted for knockout (KO), including TCR and CD3 isotypes, TCR is considered to be the more promising target because of its distinct regulatory mechanism, known as allelic exclusion ([@b22-molce-41-8-717]). T-cells are epigenetically regulated to express only one TCR chain, and thereby functional TCR disruption can be achieved by targeting the one functional TCR allele located in euchromatin ([@b34-molce-41-8-717]). The beneficial role of TCR KO in evading GvHD has recently been validated in human clinical trials, where TCR-depleted CD19 CAR-T cells successfully circumvented GvHD in two infant patients ([@b36-molce-41-8-717]).

Host versus graft effect (HvG) is another issue that must be resolved to allow development of allogenic CAR-T cells. One simple approach is to use a lymphodepleting agent to suppress the host immune system during CAR-T cell treatment. However, because these agents also have toxic effects on the infused CAR-T cells, various efforts have been made to render CAR-T cells resistant to the lymphodepleting regimens approved by the FDA. For example, [@b34-molce-41-8-717] have demonstrated that elimination of surface CD52 expression caused T-cells to become resistant to the anti-CD52 antibody, alemtuzumab. Likewise, KO of the deoxycytidine kinase (dCK) gene endowed CAR-T cells with resistance against purine nucleotide analogues such as clofarabine, fludarabine, and cytarabine ([@b50-molce-41-8-717]). Another approach to suppressing the HvG effect using gene-editing technology is to KO the β2-microglobulin (B2M) gene in T-cells, which can prevent alloantigen presentation by infused T-cells ([@b37-molce-41-8-717]). Together, these studies have clearly demonstrated that gene editing has great promise for resolving problems associated with autologous CAR-T cells, although further clinical investigations are needed to validate these approaches.

Broadening CAR target antigens for blood cancers
------------------------------------------------

Although CAR-T cell therapies have shown successful clinical outcomes, especially in B-cell malignancies, developing therapeutic CAR-T cells in certain other types of blood cancers is still unachievable due to a lack of proper tumor-specific antigens. Choosing proper target antigens is one of the most important factors determining successful clinical outcomes of CAR-T cell therapy. A good target antigen should meet two prerequisites. First, it should be ubiquitously expressed on all tumor cells. Second, to minimize off-target toxicity of CAR-T cells, the expression of target antigens should be exclusively confined to the tumor cells. In this respect, it is often extremely hard to find proper target antigens for he-matological malignancies because most antigens found on malignant cells are also found on normal T-cells, which can lead to unintended decreases in CAR-T manufacturing yield and loss of potency ([@b2-molce-41-8-717]; [@b3-molce-41-8-717]; [@b9-molce-41-8-717];[@b11-molce-41-8-717]; [@b33-molce-41-8-717]). In cases of T-cell malignancy, CD4, CD5, and CD7 have been intensively targeted by CAR-based therapies because they are ubiquitously expressed in malignant T-cells. However, many studies have consistently observed fratricidal effects of such targeting. For example, transduction of CAR-T cells targeting CD4, CD5, or CD7 caused depletion of CD4-positive, CD5-positive, or CD7-positive CAR-T cells, respectively, significantly reducing overall CAR-T cell yield ([@b3-molce-41-8-717]; [@b6-molce-41-8-717]; [@b33-molce-41-8-717]). Also, continuous interaction of CAR-T cells with target antigens during T-cell expansion significantly reduced their anti-tumor efficacy, presumably due to decrease in CAR expression and T-cell exhaustion ([@b3-molce-41-8-717]; [@b6-molce-41-8-717]). Other studies have deployed alternative immune cells, such as anti-CD5 CAR NK, to detour the self-killing effect of CAR-T cells ([@b2-molce-41-8-717]). However, considering the strong therapeutic potential of T-cells, a novel engineering strategy is desperately needed to generate fratricide-resistant CAR-T cells. To tackle this problem, [@b4-molce-41-8-717] and [@b6-molce-41-8-717] targeted CD5 and CD7 using CRISPR/Cas9, respectively, which successfully suppressed surface expression of CD5 and CD7 in CAR-T cells. They found that such knockouts prevented the self-killing effect of CAR-T cells and potentiated anti-tumor activity ([@b3-molce-41-8-717]; [@b6-molce-41-8-717]; [@b33-molce-41-8-717]).

Targeting the CS1 antigen for multiple myeloma was also challenging because it is ubiquitously expressed by activated T-cells. To circumvent the potential fratricide effect of anti-CS1 CAR-T cells, [@b9-molce-41-8-717] inactivated CS1 using a TALEN, successfully preventing the loss of CS1-positive CAR-T cells during T-cell expansion. Collectively, disruption of CAR target antigens in T-cells not only prevents fratricide but also increases the anti-tumor efficacy of CAR-T cells by circumventing T-cell exhaustion and CAR down-regulation.

Enhancing anti-tumor activity of CAR-T therapy
----------------------------------------------

Despite their remarkable success in treatment of B-cell malignancies, CAR-T cell therapies against solid tumor have largely failed. The poor anti-tumor response of CAR-T cells against solid tumors results in part from immunosuppressive mechanisms. One such mechanism is the result of prolonged T-cell activation. Studies have shown that although the serial killing capacity CAR-T cells allows effective tumor regression in TME where the tumor cells outnumber CAR-T cells ([@b14-molce-41-8-717]), repetitive tumor encountering can dampen effector functions by reprogramming CAR-T cells toward an exhausted state ([@b31-molce-41-8-717]; [@b45-molce-41-8-717]). Conventionally, strong, constitutive promoters such as EF1α or LTR have been used to express CARs. However, strong, unregulated CAR expression can result in accelerated T-cell differentiation and exhaustion ([@b5-molce-41-8-717]). Eyquem et al. demonstrated that incorporation of a CAR gene into the TRAC locus using CRISPR/Cas9 enables transcriptional regulation of CAR similar to TCR during antigen challenging. The resulting optimally controlled CAR expression kinetics successfully sustained T-cell function, circumventing T-cell exhaustion induced by repetitive activation. Besides improving T-cell function, integration of the CAR sequence at the TCR locus allowed generation of off-the-shelf CAR-T cells, supporting the versatility of this CAR knock-in approach.

CAR-T cell activity in TME can also be compromised by multi-dimensional immunosuppressive mechanisms mediated by PD1, LAG3, and DGK ([@b26-molce-41-8-717]; [@b39-molce-41-8-717]; [@b44-molce-41-8-717]). To resolve this problem, many studies have used checkpoint inhibitors, such as anti-PD1 or anti-LAG3 blockade, to invigorate exhausted CAR-T cells ([@b20-molce-41-8-717]). However, systemic delivery of checkpoint blockade often causes significant adverse clinical effects by increasing autoimmune responses ([@b25-molce-41-8-717]). To avoid both PD-1-mediated immunosuppression and the adverse effects of checkpoint blockade, PD-1 KO has been carried out in T-cells. PD-1 KO improves anti-tumor efficacy of CAR-T in various blood and solid tumor mouse models, presumably by enhancing effector function and survival of T-cells in TME ([@b23-molce-41-8-717]; [@b48-molce-41-8-717]; [@b40-molce-41-8-717]). In a seminal report from University of Pennsylvania, however, it was revealed that PD1 KO T-cells are susceptible to T-cell exhaustion and lack long-term durability, although they showed enhanced short-term proliferation and cytotoxic effects ([@b27-molce-41-8-717]). Thus, long-term follow-up studies as well as clinical validation are needed to fully understand the therapeutic potential of PD-1 KO.

Another promising KO approach is to target TCR inhibitory checkpoints such as DGK. In contrast to the invigoration of the CD28 pathway by PD-1 KO, DGK KO amplifies CD3 downstream signaling, endowing CAR-T cells with resistance to TGF-β and PGE2, inhibitory molecules produced by the TME ([@b15-molce-41-8-717]; [@b39-molce-41-8-717]). DGK KO anti-EGFRvIII CAR-T cells successfully enhance tumor infiltration in a glioblastoma xenograft mouse model and improve effector functions in TME, highlighting the therapeutic potential of DGK KO to enhance anti-tumor function of CAR-T cells for solid tumors ([@b15-molce-41-8-717]).

Two other promising KO targets are LAG-3 and FASL. LAG-3 is upregulated in exhausted T-cells in multiple in vivo studies and CAR-T trials ([@b5-molce-41-8-717]; [@b10-molce-41-8-717]). However, no functional enhancement was observed in in vitro and in vivo experiments when CRISPR/Cas9-mediated LAG-3 KO was carried out in CAR-T cells ([@b51-molce-41-8-717]). FasL is present in immunosuppressive TME, promoting apoptosis and terminal differentiation of cytotoxic T cells, which can dampen the anti-tumor efficacy of CAR-T therapy ([@b17-molce-41-8-717]; [@b32-molce-41-8-717]). To circumvent FASL-mediated immunosuppression, FAS KO was carried out in T-cells ([@b38-molce-41-8-717]). Ren et al. lentivirally delivered a triple guideRNA expression cassette targeting KO of TRAC, PD-1, and FAS. The three guideRNAs, under the control of three different promoters (human U6, mouse U6, and H1) successfully produced triple KO CAR-T cells that showed reduced Activation Induced Cell Death (AICD) and superior expansion capability. These studies support the strong promise of CRISPR/Cas9 as a tool for multiplex genome editing as well as the beneficial role of FAS KO in enhancing T-cell survival.

Safety concerns
---------------

Although gene-editing technologies can be effectively deployed to address the limitations of conventional CAR-T therapy, there exist potential safety risks. One of the major concerns of gene-editing-based therapies is off-target effects, since unintended off-target mutagenesis might ablate tumor-suppressor genes or activate oncogenes. A series of recent studies have reported off-target effects in T-cells. Using an IDLV gene-trapping assay, 10 potential off-target sites were detected in T-cells treated with megaTAL, none of which occurred in an exon region ([@b28-molce-41-8-717]). Ren, Liu et al. have observed marginal off-target effects in CAR-T cells electroporated with CRISPR/Cas9 targeting TRAC or TRBC ([@b37-molce-41-8-717]), and showed that the use of high-fidelity Cas9 successfully eliminates off-target effects observed with the use of conventional Cas9, while maintaining on-target knockout efficiency ([@b37-molce-41-8-717]; [@b47-molce-41-8-717]). To manage the safety risk of off-target effects, careful selection of target site combined with unbiased off-target assays are required ([@b49-molce-41-8-717]).

Another safety concern is that multiplex gene editing can lead to translocations between double-strand break sites. Such events were detected at a rate of 1×10^−4^ --2×10^−2^ in human T-cells treated with two TALEN mRNAs targeting TRAC and CD52 ([@b34-molce-41-8-717]). Although no proliferative advantage was detected in T-cells that underwent translocation, thorough transformation analysis is needed to ensure the safety of gene-edited CAR-T therapies.

Lastly, besides the safety risk elicited by gene-editing per se, such as off-target effects and translocation, the altered function of gene-edited CAR-T cell can induce adverse effects in the clinic. For example, upregulated effector functions and hyperproliferative capacity of PD1 KO CAR-T cells can cause severe systemic inflammation, such as cytokine release syndrome (CRS), as observed in multiple CD19-CAR-T studies ([@b18-molce-41-8-717]; [@b35-molce-41-8-717]). The long-term safety profile of PD-1 KO CAR-T should be further examined in the clinic ([Table 1](#t1-molce-41-8-717){ref-type="table"}).

LIMITATIONS OF CURRENT GENE-EDITING METHODS
===========================================

In the past, effective genome engineering of primary T-cell was unachievable due to low transfection efficiencies. But recent advances in electroporation tools as well as T-cell activation methods allow highly efficient gene editing in primary T-cells. However, there are still challenges remaining in current T-cell engineering methodology. First, CRISPR/Cas9-mediated gene-editing can induce apoptosis and growth retardation in engineered T-cells, partially attributable to p53-mediated DNA damage and type I interferon responses ([@b12-molce-41-8-717]; [@b16-molce-41-8-717]). Since doubling times of T-cells in the initial expansion phase is 8--11 h, 1--2 days of growth inhibition after electroporation can result in significant decrease in total CAR-T cell yield. Using modified guideRNAs, such as 5'hydroxyl guideRNA or 2'O-methyl guideRNA, has been reported to alleviate the type I interferon immune response, thereby enhancing CAR-T manufacturing ([@b16-molce-41-8-717]; [@b28-molce-41-8-717]). Also, compared to high KO efficiency in primary T-cells (70--90%), the knockin (KI) efficiency is relatively low ([@b28-molce-41-8-717]; [@b34-molce-41-8-717]; [@b37-molce-41-8-717]). Several groups have reported 10--50% CAR KI efficiency using MegaTAL or CRISPR/Cas9 in combination with AAV6-mediated delivery of a homologous recombination donor ([@b5-molce-41-8-717]; [@b42-molce-41-8-717]). Suppression of the p53 pathway during gene-editing has been shown to increase the rate of homologous recombination in retinal pigment epithelial cells and human pluripotent stem cells, however this approach has not yet been validated in human primary T-cells ([@b12-molce-41-8-717]; [@b13-molce-41-8-717]).

CONCLUSIONS
===========

In AUGUST 2017, Tisagenlecleucel, the first genetically engineered cellular drug, was approved by the US FDA with unprecedented clinical outcomes, followed by approval of axi-cabtagene ciloleucel in October. Since then, there has been growing interest in developing next-generation CAR-T cell therapy, including by the use of gene-editing technologies ([Table 1](#t1-molce-41-8-717){ref-type="table"}, Clinicaltrials.gov). The advent of CRISPR/Cas9 and off-target analysis tools has enabled effective and precise genome-engineering of CAR-T cells, and thereby these technologies are expected to resolve the following three unmet medical needs of current CAR-T cell therapy ([Fig. 1](#f1-molce-41-8-717){ref-type="fig"}). First, gene-editing allows development of off-the-shelf universal CAR-T cells by alleviating GvH and HvG, which can significantly improve CAR-T manufacturing at reduced cost and in shorter time. Second, gene-editing can broaden the range of usable CAR target antigens in blood cancers, otherwise untargetable, by preventing CAR-T fratricide. Third, gene-editing enhances anti-tumor responses by circumventing T-cell hypofunction caused by continuous cell activation and immunosuppressive effects of the TME, which may expand the use of CAR-T cell therapy for solid tumors. Because full understanding of the TME immunosuppressive mechanism is still elusive, there are as yet no clinically validated KO targets for clinical applications. Comprehensive analysis of the TME will reveal robust targets for gene-editing to improve efficacy of CAR-T cells. Although potential safety concerns of gene-editing technologies still need to be resolved, the promising outcomes of gene-edited CAR-T cell therapy may offset the risks. In conclusion, unequivocally, gene-editing technologies, especially CRISPR/Cas9 alongside further understanding of T-cell exhaustion, TME, and clinical outcomes, will ensure the development of more potent CAR-T cell therapies.
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Overview of clinical trials of CAR-T cell therapy.

Registered clinical trials of CAR-T cell therapies using gene-editing. Of 11 trials, CRISPR/Cas9 was used as an editing tool in 9 trials, and TALENs in 2 trials

  NCT Number    Gene Editing Tool                       Target gene                                                                                                       T-cell                                  Indication                                                     Country                                                Group
  ------------- --------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------- ------------------------------------------------------ ----------------------------
  NCT03399448   CRISPR                                  TCR/PD-1                                                                                                          NYESO-1 TCR-T                           MM/Melanoma/Synovial Sarcoma /Myeloid/Round Cell Liposarcoma   US                                                     University of Pennsylvania
  NCT03166878   TCR/B2M                                 CD19 CAR-T                                                                                                        B-cell Leukemia/Lymphoma                China                                                          Chinese PLA General Hospital                           
  NCT03398967   TCR                                     Dual specific CD19 and CD20/CD22 CAR-T                                                                            B-cell Leukemia/Lymphoma                China                                                          Chinese PLA General Hospital                           
  NCT03081715   PD-1                                    Endogenous T-cell                                                                                                 Esophageal Cancer                       China                                                          Hangzhou Cancer Hospital Anhui Kedgene Biotechnology   
  NCT02863913   Invasive Bladder Cancer Stage IV        China                                                                                                             Peking University /Cell Biotech                                                                                                                               
  NCT02867345   Hormone Refractory Prostate Cancer      China                                                                                                             Peking University /Cell Biotech                                                                                                                               
  NCT02867332   Metastatic Renal Cell Carcinoma         China                                                                                                             Peking University/Cell Biotech                                                                                                                                
  NCT02793856   Metastatic Non-small Cell Lung Cancer   China                                                                                                             Sichuan University/Chengdu MedGenCell                                                                                                                         
  NCT03044743   EBV-CTL                                 Gastric Carcinoma Nasopharyngeal Carcinoma T-Cell Lymphoma Adult Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma   China                                   Nanjing Drum Tower Hospital                                                                                           
  NCT02746952   TALEN                                   TCR/CD52                                                                                                          GD19 CAR-T                              Relapsed/refractory B-ALL                                      US/Europe                                              Servier
  NCT03190278   TCR                                     CD123 CAR-T                                                                                                       Acute Myeloid Leukemia                  US                                                             Cellectis                                              
